Evidence map›Paper›PMID 35914228›Full record

ArticleBlood advances2023

Disruption of stem cell niche-confined R-spondin 3 expression leads to impaired hematopoiesis.

Antonina V Kurtova, Melanie Heinlein, Simon Haas, Lars Velten, Gerrit J P Dijkgraaf, Elaine E Storm, Noelyn M Kljavin, Soufiane Boumahdi, Patricia Himmels, Aurelie Herault and 11 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 5 countries.

Antonina V KurtovaMolecular Oncology, Genentech, South San Francisco, CA.
Melanie HeinleinMolecular Oncology, Genentech, South San Francisco, CA.ORCID 0000-0001-6194-7159
Simon HaasHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.ORCID 0000-0001-9227-2051
Lars VeltenCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0002-1233-5874
Gerrit J P DijkgraafMolecular Oncology, Genentech, South San Francisco, CA.
Elaine E StormMolecular Oncology, Genentech, South San Francisco, CA.
Noelyn M KljavinMolecular Oncology, Genentech, South San Francisco, CA.
Soufiane BoumahdiMolecular Oncology, Genentech, South San Francisco, CA.
Patricia HimmelsMolecular Oncology, Genentech, South San Francisco, CA.ORCID 0000-0001-6210-7688
Aurelie HeraultMolecular Oncology, Genentech, South San Francisco, CA.
Andrew ManciniMolecular Oncology, Genentech, South San Francisco, CA.
Hartmut KoeppenResearch Pathology, Genentech, South San Francisco, CA.ORCID 0000-0003-0923-3110
Monique DailOncology Biomarker Development, Genentech, South San Francisco, CA.ORCID 0000-0002-2687-8829
Qingxiang YanBiometrics Department, Hoffmann-La Roche, Mississauga, ON, Canada.
Jianhuan ZhangBiochemical and Cellular Pharmacology, Genentech, South San Francisco, CA.
Ute KochSwiss Institute for Experimental Cancer Research, EPFL, Lausanne, Switzerland.ORCID 0000-0001-7914-7061
Freddy RadtkeSwiss Institute for Experimental Cancer Research, EPFL, Lausanne, Switzerland.
Zora ModrusanMolecular Biology, Genentech, South San Francisco, CA.
Ciara MetcalfeDiscovery Oncology, Genentech, South San Francisco, CA.ORCID 0000-0001-7233-661X
Robert PiskolOncology Bioinformatics, Genentech, South San Francisco, CA.ORCID 0000-0001-8942-9943
Frederic J de SauvageMolecular Oncology, Genentech, South San Francisco, CA.ORCID 0000-0002-5275-2584
Molecular Oncology (United States) · USÉcole Polytechnique Fédérale de Lausanne · CHGerman Cancer Research Center · DERoche (Canada) · CASunny BioDiscovery (United States) · USUniversitat Pompeu Fabra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Self-renewal and differentiation of stem and progenitor cells are tightly regulated to ensure tissue homeostasis. This regulation is enabled both remotely by systemic circulating cues, such as cytokines and hormones, and locally by various niche-confined factors. R-spondin 3 (RSPO3) is one of the most potent enhancers of Wnt signaling, and its expression is usually restricted to the stem cell niche where it provides localized enhancement of Wnt signaling to regulate stem cell expansion and differentiation. Disruption of this niche-confined expression can disturb proper tissue organization and lead to cancers. Here, we investigate the consequences of disrupting the niche-restricted expression of RSPO3 in various tissues, including the hematopoietic system. We show that normal Rspo3 expression is confined to the perivascular niche in the bone marrow. Induction of increased systemic levels of circulating RSPO3 outside of the niche results in prominent loss of early B-cell progenitors and anemia but surprisingly has no effect on hematopoietic stem cells. Using molecular, pharmacologic, and genetic approaches, we show that these RSPO3-induced hematopoietic phenotypes are Wnt and RSPO3 dependent and mediated through noncanonical Wnt signaling. Our study highlights a distinct role for a Wnt/RSPO3 signaling axis in the regulation of hematopoiesis, as well as possible challenges related to therapeutic use of RSPOs for regenerative medicine.

Indexed as

HematopoiesisStem Cell NicheCell DifferentiationHematopoietic Stem CellsWnt Signaling Pathway

Identifiers

PMID35914228
PMCPMC9979769
OpenAlexW4289278153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.